LUND, Sweden, Oct. 28, 2008-Active Biotech (NASDAQ OMX Nordic: ACTI) has presented data regarding the 57-57 project at the American College of Rheumatology (ACR) Annual Scientific Meeting, a premier event for specialists in the field of rheumatology, held in San Francisco October 24-29*. In a completed Phase Ib trial twelve patients have been treated for 84 days at various dose levels of ABR-215757. The maximum tolerable dose (MTD) for ABR-215757 was defined as 4.5 mg/day. The overall safety profile throughout the study was very favorable. In a subset of patients treated with 4.5 mg/day ABR-215757 the global gene expression pattern was investigated at various time points after treatment. The new data presented indicate that treatment with ABR-215757 modulates gene expression related to immune function. Among these genes were...
[read full story]
Your Web Site
